The Fort Worth Press - Drew Weissman, Nobel-winning mRNA pioneer

USD -
AED 3.672504
AFN 64.000368
ALL 80.660025
AMD 364.155001
ANG 1.790365
AOA 918.000367
ARS 1524.750402
AUD 1.417435
AWG 1.8
AZN 1.70397
BAM 1.716593
BBD 2.014833
BDT 123.096502
BGN 1.683441
BHD 0.377145
BIF 3013.033747
BMD 1
BND 1.278097
BOB 12.259622
BRL 5.188104
BSD 1.000307
BTN 95.794093
BWP 13.621802
BYN 3.022425
BYR 19600
BZD 2.011937
CAD 1.41345
CDF 2340.000362
CHF 0.828271
CLF 0.024357
CLP 961.770396
CNY 6.71325
CNH 6.734304
COP 3348.488173
CRC 454.820731
CUC 1
CUP 24.008426
CVE 96.778865
CZK 21.384404
DJF 178.136657
DKK 6.562804
DOP 59.49006
DZD 134.160706
EGP 51.788213
ERN 15
ETB 162.282003
EUR 0.87791
FJD 2.24725
FKP 0.754924
GBP 0.754689
GEL 2.61504
GGP 0.754924
GHS 11.618906
GIP 0.754924
GMD 73.503851
GNF 8797.998859
GTQ 7.639444
GYD 209.30355
HKD 7.842504
HNL 26.849519
HRK 6.613804
HTG 130.916751
HUF 320.61504
IDR 17914.1
ILS 3.04806
IMP 0.754924
INR 95.817504
IQD 1310.484048
IRR 1374575.000352
ISK 120.260386
JEP 0.754924
JMD 158.265678
JOD 0.70904
JPY 157.24504
KES 129.644095
KGS 87.448204
KHR 4068.10901
KMF 433.00035
KPW 900.000318
KRW 1354.240383
KWD 0.30864
KYD 0.833633
KZT 443.156186
LAK 22438.232325
LBP 89581.428007
LKR 330.293588
LRD 172.063018
LSL 16.32106
LTL 2.95274
LVL 0.60489
LYD 6.395752
MAD 9.599596
MDL 17.756616
MGA 4416.553298
MKD 54.043972
MMK 2099.36214
MNT 3596.164164
MOP 8.082152
MRU 40.243999
MUR 47.530378
MVR 15.450378
MWK 1734.585509
MXN 17.760378
MYR 4.074104
MZN 63.910377
NAD 16.32106
NGN 1326.380377
NIO 36.810462
NOK 9.50785
NPR 153.270725
NZD 1.749629
OMR 0.385571
PAB 1.000307
PEN 3.395971
PGK 4.456927
PHP 62.347038
PKR 277.197262
PLN 3.83775
PYG 5896.344407
QAR 3.646377
RON 4.629204
RSD 103.085092
RUB 84.346338
RWF 1478.474569
SAR 3.755913
SBD 8.000512
SCR 13.863038
SDG 601.503676
SEK 9.91775
SGD 1.278404
SHP 0.755002
SLE 24.650371
SLL 20969.491881
SOS 571.729495
SRD 37.667504
STD 20697.981008
STN 21.503489
SVC 8.753236
SYP 13002.000254
SZL 16.317198
THB 33.375038
TJS 9.228244
TMT 3.51
TND 2.961425
TOP 2.40776
TRY 48.942504
TTD 6.803879
TWD 31.728704
TZS 2654.934831
UAH 44.794751
UGX 3918.023434
UYU 40.075482
UZS 11839.206565
VES 852.43145
VND 25976
VUV 118.388248
WST 2.745723
XAF 575.871484
XAG 0.015553
XAU 0.000233347179
XCD 2.70255
XCG 1.80287
XDR 0.707052
XOF 575.871484
XPF 104.673717
YER 236.650363
ZAR 16.190363
ZMK 9001.203584
ZMW 19.513758
ZWL 321.999592
SSP 5712.591904
MXV 2.012596
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman, Nobel-winning mRNA pioneer / Photo: © AFP

Drew Weissman, Nobel-winning mRNA pioneer

Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.

Text size:

The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.

His next quests include, among others, developing a vaccine against all future coronaviruses.

"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.

"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."

- Twin breakthroughs-

The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.

But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.

"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.

In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.

"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.

"We sat there staring at our phones for five years, and they never rang!"

With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."

Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.

- Helping people -

Weissman grew up in Lexington, Massachusetts.

His father and mother, both since retired, were an engineer and dental hygienist, respectively.

"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.

He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.

As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.

Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.

"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.

Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.

Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.

Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.

Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.

M.T.Smith--TFWP